✦ LIBER ✦

Biodistribution, radiation dosimetry and scouting of90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using89Zr-ibritumomab tiuxetan and PET

✍ Scribed by Saiyada N. F. Rizvi; Otto J. Visser; Maria J. W. D. Vosjan; Arthur van Lingen; Otto S. Hoekstra; Josée M. Zijlstra; Peter C. Huijgens; Guus A. M. S. van Dongen; Mark Lubberink

Publisher: Springer
Year: 2012
Tongue: English
Weight: 284 KB
Volume: 39
Category: Article
ISSN: 0340-6997
DOI: 10.1007/s00259-011-2008-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy of external beam rad

Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy

✍ Terry E. Justice; James A. Martenson; Gregory A. Wiseman; Thomas E. Witzig 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

Long-term responses in patients with rec

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

✍ Thomas E. Witzig; Arturo Molina; Leo I. Gordon; Christos Emmanouilides; Russell 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB

## Abstract ## BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non‐Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. ## METHODS. Data on patients with recurring NHL treated w